⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 2, 2024EJNMMI Radiopharmacy and ChemistryOpen Access

GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport

Mélodie Ferrat Mohammad Mahdi Moein Carmen Cananau Tetyana Tegnebratt Paul Saliba Fredrik Norman Carsten Steiger Klas Bratteby Erik Samén Kenneth Dahl Thuy Tran

View Full Paper

Ask AI

Bookmark

Share

Abstract

Parkinson's disease is a neurodegenerative disorder that is characterized by a degeneration of the dopaminergic system. Dopamine transporter (DAT) positron emission tomography (PET) imaging has emerged as a powerful and non-invasive method to quantify dopaminergic function in the living brain. The PET radioligand, [

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ferrat et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd48b6db64358763df77 https://doi.org/10.1186/s41181-024-00269-9

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1GMP Production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a Radiotracer for in vivo PET Imaging of the Dopamine Transport2024
2Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis2024 · 3 citations
3Evaluation of Damage Discrimination in Dopaminergic Neurons Using Dopamine Transporter PET Tracer [18F]FECNT-d42024
4Cross-Tracer Synthesis Model of <sup>11</sup> C-CFT and <sup>18</sup> F-DOPA PET Images from <sup>18</sup> F-FDG for Parkinson's DiseaseOriginal Research · 2026
5Positron Emission Tomography: Updates on Imaging of Addictionreview · 2019 · 9 citations